IDX184 addendum: These data ought to be good enough for IDIX to ink a nice partnership deal—either for IDX184 alone or for a package of IDX184 and one or more of IDIX’s other HCV drug candidates.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”